Washington Post: Merck’s experimental pill to treat covid-19 cuts risk of hospitalization and death in half, the pharmaceutical company reports

Washington Post: Merck’s experimental pill to treat covid-19 cuts risk of hospitalization and death in half, the pharmaceutical company reports. “Merck announced Friday that an experimental pill it developed to treat covid-19 reduced the risk of hospitalization and death by nearly half in a clinical trial. An independent board of experts monitoring the trial recommended the study be stopped early because of the positive results, a significant and telling step in a pharmaceutical study. Merck and partner Ridgeback Biotherapeutics said in a news release they would apply for emergency use authorization for the drug, molnupiravir, in the United States as soon as possible. It would be the first antiviral pill for covid-19.”

Leave a Reply

%d bloggers like this: